{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-grade+Gliomas+%28HGG%29&page=2", "query": { "condition": "High-grade Gliomas (HGG)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-grade+Gliomas+%28HGG%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-22T06:08:40.309Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02684058", "title": "Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Astrocytoma", "Anaplastic Astrocytoma", "Astrocytoma", "Oligodendroglioma, Childhood", "Anaplastic Oligodendroglioma", "Glioblastoma", "Pilocytic Astrocytoma", "Giant Cell Astrocytoma", "Pleomorphic Xanthoastrocytoma", "Anaplastic Pleomorphic Xanthoastrocytoma", "Angiocentric Glioma", "Chordoid Glioma of Third Ventricle", "Gangliocytoma", "Ganglioglioma", "Anaplastic Ganglioglioma", "Dysplastic Gangliocytoma of Cerebrellum", "Desmoplastic Infantile Astrocytoma and Ganglioglioma", "Papillary Glioneuronal Tumor", "Rosette-forming Glioneurona Tumor", "Central Neurocytoma", "Extraventricular Neurocytoma", "Cerebellar Iponeurocytoma" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Months to 17 Years" }, "enrollment_count": 151, "start_date": "2017-12-28", "completion_date": "2023-04-28", "has_results": true, "last_update_posted_date": "2023-12-13", "last_synced_at": "2026-07-22T06:08:40.309Z", "location_count": 10, "location_summary": "Orange, California • Washington D.C., District of Columbia • Miami, Florida + 7 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02684058" }, { "nct_id": "NCT04323046", "title": "Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Malignant Glioma", "Recurrent Glioblastoma", "Recurrent Malignant Glioma", "Recurrent Grade III Glioma", "Grade III Glioma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Sabine Mueller, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "25 Years", "sex": "ALL", "summary": "6 Months to 25 Years" }, "enrollment_count": 9, "start_date": "2020-10-02", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-07-22T06:08:40.309Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04323046" }, { "nct_id": "NCT03434262", "title": "SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Ependymoma", "Anaplastic Ganglioglioma", "Anaplastic Meningioma", "Anaplastic Oligodendroglioma", "Pleomorphic Xanthoastrocytoma, Anaplastic", "Atypical Teratoid/Rhabdoid Tumor", "Brain Cancer", "Brain Tumor", "Central Nervous System Neoplasms", "Choroid Plexus Carcinoma", "CNS Embryonal Tumor With Rhabdoid Features", "Ganglioneuroblastoma of Central Nervous System", "CNS Tumor", "Embryonal Tumor of CNS", "Ependymoma", "Glioblastoma", "Glioma", "Glioma, Malignant", "Medulloblastoma", "Medulloblastoma; Unspecified Site", "Medulloepithelioma", "Neuroepithelial Tumor", "Neoplasms", "Neoplasms, Neuroepithelial", "Papillary Tumor of the Pineal Region (High-grade Only)", "Pediatric Brain Tumor", "Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)", "Pineoblastoma", "Primitive Neuroectodermal Tumor", "Recurrent Medulloblastoma", "Refractory Brain Tumor", "Neuroblastoma. CNS", "Glioblastoma, IDH-mutant", "Glioblastoma, IDH-wildtype", "Medulloblastoma, Group 3", "Medulloblastoma, Group 4", "Glioma, High Grade", "Neuroepithelial Tumor, High Grade", "Medulloblastoma, SHH-activated and TP53 Mutant", "Medulloblastoma, SHH-activated and TP53 Wildtype", "Medulloblastoma, Chromosome 9q Loss", "Medulloblastoma, Non-WNT Non-SHH, NOS", "Medulloblastoma, Non-WNT/Non-SHH", "Medulloblastoma, PTCH1 Mutation", "Medulloblastoma, WNT-activated", "Ependymoma, Recurrent", "Glioma, Recurrent High Grade", "Glioma, Recurrent Malignant", "Embryonal Tumor, NOS", "Glioma, Diffuse Midline, H3K27M-mutant", "Embryonal Tumor With Multilayered Rosettes (ETMR)", "Ependymoma, NOS, WHO Grade III", "Ependymoma, NOS, WHO Grade II", "Medulloblastoma, G3/G4", "Ependymoma, RELA Fusion Positive" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "ribociclib", "type": "DRUG" }, { "name": "sonidegib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "39 Years", "sex": "ALL", "summary": "1 Year to 39 Years" }, "enrollment_count": 68, "start_date": "2018-03-05", "completion_date": "2024-05-24", "has_results": false, "last_update_posted_date": "2024-05-31", "last_synced_at": "2026-07-22T06:08:40.309Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434262" }, { "nct_id": "NCT03330197", "title": "A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pediatric Brain Tumor", "Diffuse Intrinsic Pontine Glioma" ], "interventions": [ { "name": "Ad-RTS-hIL-12", "type": "BIOLOGICAL" }, { "name": "Oral Veledimex - Arm 1 (Pediatric Brain Tumor)", "type": "DRUG" }, { "name": "Oral Veledimex - Arm 2 (DIPG)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alaunos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "0 Years to 21 Years" }, "enrollment_count": 6, "start_date": "2017-09-26", "completion_date": "2021-09-10", "has_results": true, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-07-22T06:08:40.309Z", "location_count": 3, "location_summary": "San Francisco, California • Chicago, Illinois • Boston, Massachusetts", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03330197" }, { "nct_id": "NCT06528691", "title": "Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Glioma", "CNS Tumor" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "G-CSF", "type": "BIOLOGICAL" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "3 Years", "sex": "ALL", "summary": "Up to 3 Years" }, "enrollment_count": 52, "start_date": "2026-05-01", "completion_date": "2032-11", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-07-22T06:08:40.309Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06528691" }, { "nct_id": "NCT03257631", "title": "A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Central Nervous System Neoplasms", "Medulloblastoma" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 53, "start_date": "2017-09-18", "completion_date": "2023-09-14", "has_results": true, "last_update_posted_date": "2024-04-16", "last_synced_at": "2026-07-22T06:08:40.309Z", "location_count": 6, "location_summary": "Stanford, California • Gainesville, Florida • Chicago, Illinois + 3 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03257631" }, { "nct_id": "NCT04730349", "title": "A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ependymoma", "Ewing Sarcoma", "High-grade Glioma", "Leukemia and Lymphoma", "Medulloblastoma", "Miscellaneous Brain Tumors", "Miscellaneous Solid Tumors", "Neuroblastoma", "Relapsed, Refractory Malignant Neoplasms", "Rhabdomyosarcoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "NKTR-214", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 15, "start_date": "2021-06-03", "completion_date": "2022-06-22", "has_results": true, "last_update_posted_date": "2023-03-24", "last_synced_at": "2026-07-22T06:08:40.309Z", "location_count": 2, "location_summary": "Little Rock, Arkansas • St Louis, Missouri", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04730349" }, { "nct_id": "NCT01985256", "title": "Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Anaplastic Oligoastrocytoma" ], "interventions": [ { "name": "Toca 511", "type": "BIOLOGICAL" }, { "name": "Toca FC", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Tocagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 17, "start_date": "2014-02", "completion_date": "2016-03-03", "has_results": false, "last_update_posted_date": "2018-05-21", "last_synced_at": "2026-07-22T06:08:40.309Z", "location_count": 6, "location_summary": "Irvine, California • Los Angeles, California • San Diego, California + 3 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Edison", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01985256" }, { "nct_id": "NCT06072586", "title": "A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "High Grade Glioma", "Glioblastoma" ], "interventions": [ { "name": "BDTX-1535", "type": "DRUG" }, { "name": "BDTX-1535 combined with radiation therapy", "type": "DRUG" }, { "name": "BDTX-1535 combined with temozolomide and radiation therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Joseph's Hospital and Medical Center, Phoenix", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2023-10-18", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-11-20", "last_synced_at": "2026-07-22T06:08:40.309Z", "location_count": 2, "location_summary": "Chandler, Arizona • Phoenix, Arizona", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06072586" }, { "nct_id": "NCT05843253", "title": "Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Glioma", "Diffuse Intrinsic Pontine Glioma", "Anaplastic Astrocytoma", "Glioblastoma", "Glioblastoma Multiforme", "Diffuse Midline Glioma, H3 K27M-Mutant", "Metastatic Brain Tumor", "WHO Grade III Glioma", "WHO Grade IV Glioma", "Diffuse Hemispheric Glioma, H3 G34-Mutant" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "39 Years", "sex": "ALL", "summary": "12 Months to 39 Years" }, "enrollment_count": 120, "start_date": "2024-08-22", "completion_date": "2034-08-28", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-07-22T06:08:40.309Z", "location_count": 11, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 8 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05843253" } ] }